

FOI.17034 - Attachment 1

DRUG(S)	1. Total number of patients treated with the listed medications for any indication		2. Number of patients for whom Hormone Therapy was initiated		3. Number of patients for whom Hormone Therapy was continued for		4. Number of patients that were initiated on Docetaxel	
	1 January to 31 December 2023	1 January to 31 December 2024	1 January to 31 December 2023	1 January to 31 December 2024	1 January to 31 December 2023	1 January to 31 December 2024	1 January to 31 December 2023	1 January to 31 December 2024
ADT* alone	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Abiraterone (Zytiga) in combination with any ADT	63	99	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Abiraterone (Zytiga) – no ADT			Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Enzalutamide (Xtandi) in combination with any ADT	64	62	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Enzalutamide (Xtandi) – no ADT			Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Apalutamide (Erleada) in combination with any ADT	13	30	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Darolutamide (Nubeqa) in combination with any ADT	12	20	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Darolutamide (Nubeqa) in combination with any ADT and docetaxel / cabazitaxel			Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
Docetaxel in combination with any ADT	34	34	Section 12 exemption applied		Section 12 exemption applied		Section 12 exemption applied	
							Total 27	Total 25

* By ADT we mean any of the following: Goserelin (Zoladex), Leuprorelin acetate (Prostap), Triptorelin (Decapeptyl), Buserelin acetate (Suprefact), Degarelix (Firmagon), Relugolix (Orgovyx)